TWI554510B - ３－［（３－｛［４－（４－嗎啉基甲基）－１ｈ－吡咯－２－基］亞甲基｝－２－側氧基－２，３－二氫－１ｈ－吲哚－５－基）甲基］－１，３－噻唑啶－２，４－二酮之新穎鹽，其製備方法，及包含其之調配物 - Google Patents
３－［（３－｛［４－（４－嗎啉基甲基）－１ｈ－吡咯－２－基］亞甲基｝－２－側氧基－２，３－二氫－１ｈ－吲哚－５－基）甲基］－１，３－噻唑啶－２，４－二酮之新穎鹽，其製備方法，及包含其之調配物 Download PDFInfo
- Publication number
- TWI554510B TWI554510B TW103124019A TW103124019A TWI554510B TW I554510 B TWI554510 B TW I554510B TW 103124019 A TW103124019 A TW 103124019A TW 103124019 A TW103124019 A TW 103124019A TW I554510 B TWI554510 B TW I554510B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- cancer
- methyl
- pyrrol
- morpholinylmethyl
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims description 9
- 239000000203 mixture Substances 0.000 title description 7
- 238000002360 preparation method Methods 0.000 title description 4
- AREYWCZYVPSHGS-UHFFFAOYSA-N 3-[[3-[[4-(morpholin-4-ylmethyl)-1h-pyrrol-2-yl]methylidene]-2-oxo-1h-indol-5-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1CC1=CC=C(NC(=O)C2=CC=3NC=C(CN4CCOCC4)C=3)C2=C1 AREYWCZYVPSHGS-UHFFFAOYSA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 29
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 28
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 23
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 5
- -1 2-oxo-2,3-dihydro-1H-indol-5-yl Chemical group 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 229910002056 binary alloy Inorganic materials 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 4
- 239000007858 starting material Substances 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010055006 Pancreatic sarcoma Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000002526 pancreas sarcoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 230000005540 biological transmission Effects 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims 2
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 231100000024 genotoxic Toxicity 0.000 claims 1
- 230000001738 genotoxic effect Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000007937 lozenge Substances 0.000 description 5
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- FPSAJUOIYZSJJA-UHFFFAOYSA-N 3-[[3-[[4-(morpholin-4-ylmethyl)-1h-pyrrol-2-yl]methylidene]-2-oxo-1h-indol-5-yl]methyl]-1,3-thiazolidine-2,4-dione;hydrochloride Chemical compound Cl.O=C1CSC(=O)N1CC1=CC=C(NC(=O)C2=CC=3NC=C(CN4CCOCC4)C=3)C2=C1 FPSAJUOIYZSJJA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- GXGJIOMUZAGVEH-UHFFFAOYSA-N Chamazulene Chemical group CCC1=CC=C(C)C2=CC=C(C)C2=C1 GXGJIOMUZAGVEH-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920003223 poly(pyromellitimide-1,4-diphenyl ether) Polymers 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本發明係關於一種下式(I)之3-[(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮之新穎鹽：
其製備方法且亦關於包含其之醫藥組合物。
3-[(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮在癌學領域具有極有價值的藥理性質。實際上，已顯示3-[(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮具有抑制癌細胞遷移之能力，此使其尤其可用於治療癌症，及更尤其可用於治療實體轉移性腫瘤。在可治療的癌症中，可尤其提及(但不意味任何限制)結腸癌、乳癌、肝癌、腎癌、腦癌及食道癌、黑素
瘤、骨髓瘤、卵巢癌、非小細胞性肺癌、小細胞性肺癌、前列腺癌及胰臟癌及肉瘤。
3-[(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮及其與醫藥上可接受之酸的加成鹽及更尤其係其鹽酸鹽之製備及治療用途已描述於(例如)歐洲專利說明書EP 2281822中。
鑒於該化合物的醫藥價值，重要的是能以極佳產率及高純度及極佳可再現性得到該活性化合物。已很快發現所使用的鹽酸鹽呈現純化及再結晶及極難以使產率最佳化之問題。此外，已觀察到所得之活性化合物之可再現性及一致性的問題。在許多研究試驗之後，可確定一種結合各種優勢(尤其係關於純化、獲得方法的可再現性及產率的優勢)的新穎鹽，其亦出乎意料地具有極顯著地提高該活性化合物的可溶性之優勢。從物理化學及藥代動力學之角度來看，該新穎鹽因此具有對其用作藥劑而言不可缺少的所有品質。
因此，本發明係關於一種3-[(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮之新穎鹽，更尤其關於式(II)之3-[(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮甲磺酸鹽：
其中符號表示雙鍵具有組態Z或E。
本發明較佳係關於3-[(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲
基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮甲磺酸鹽之Z型異構體。
該新穎鹽具有以下優勢：以極佳產率得到其之簡單且可再現的方法；在水及有機溶劑中的溶解度增加，此使得可預期進行純化階段(例如澄清)，以提高其純度。
本發明亦係關於一種獲得3-[(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮甲磺酸鹽(更尤其指其Z型異構體)之方法，其特徵在於使用根據(例如)描述於專利說明書EP 2281822中之方法獲得之3-[(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮作為起始材料。將該二酮溶解於溶劑/水的二元系統中，然後添加1至2莫耳當量的甲磺酸，且攪拌該混合物，直至甲磺酸鹽沉澱析出。
該溶劑宜為極性溶劑，諸如(例如)乙腈、丙酮、1,4-二噁烷、四氫呋喃、N,N-二甲基甲醯胺、N,N-二甲基乙醯胺、二甲亞碸、醇(例如甲醇、乙醇及異丙醇)、水及該等溶劑的水性/有機混合物。較佳地，溶劑/水之比例將係0/100至100/0。
本發明方法之一變型包括使用3-[(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮鹽酸鹽作為起始材料；獲得該化合物之方法已描述於(例如)專利說明書EP 2281822中。將該鹽酸鹽溶解於溶劑/水的二元系統中，且藉由添加鹼將該混合物之pH調節至8。過濾排除所形成的鹽。加熱濾液，且然後添加甲磺酸。然後使溫度緩慢恢復至室溫，並濾出所得到的甲磺酸鹽。所使用之溶劑更尤其為極性溶劑，例如：乙腈、丙酮、1,4-二噁烷、四氫呋喃、N,N-二甲基甲醯胺、N,N-二甲基乙醯胺、二
甲亞碸或醇(例如甲醇、乙醇及異丙醇)。較佳地，溶劑/水之比將係70/30，及更尤其係90/10。使用過量(尤其係1至2當量)的甲磺酸。
根據本發明之式(II)化合物甚至在以下變性條件下經過一段時間後仍具有極佳安定性：在25℃/60%相對濕度下、在25℃/90%相對濕度下、在30℃/65%相對濕度下、在40℃/75%相對濕度下，或在50℃下，該式(II)化合物在6個月後仍然沒有變化。
本發明亦係關於包含本發明式(II)化合物(更尤其係其Z型異構體)作為活性成分及一種或多種適宜之惰性及無毒性赋形劑之醫藥組合物。在根據本發明之醫藥組合物中，可尤其提及彼等適合經口、非經腸(靜脈內或皮下)或經鼻投與者、錠劑或糖衣丸劑、粒劑、舌下錠劑、膠囊、糖錠、栓劑、乳劑、軟膏、皮膚用凝膠、注射製劑、可飲用懸浮液及咀嚼膠質。
根據本發明之包含式(II)化合物(更尤其係其Z型異構體)的醫藥形式將用於治療癌症，尤其係實體轉移性腫瘤。在可治療的癌症中，可尤其提及(但不意味任何限制)結腸癌、乳癌、肝癌、腎癌、腦癌及食道癌、黑素瘤、骨髓瘤、卵巢癌、非小細胞性肺癌、小細胞性肺癌、前列腺癌及胰臟癌及肉瘤。
有效劑量可根據疾病的性質及嚴重性、投與途徑及患者年齡及重量而變化。以鹼當量計，劑量係在1mg至1g/天之間變化(一或多次投藥)。
以下實例闡述本發明，但不以任何方式加以限制。
實例1：3-[(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮甲磺酸鹽，Z型異構體
將1.26g 3-[(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮加入100mL燒瓶
中。在添加20ml之乙腈/水(90/10)的溶液後，在70℃下加熱該混合物。製備含有2ml甲磺酸及50ml的乙腈/水(90/10)混合物的溶液。將5ml所得溶液加入反應混合物中，該混合物隨後變澄清。冷卻該混合物至20℃(0.5℃/min，在200rpm下攪拌)。在室溫下隔夜攪拌後，藉由過濾單離該標題產物，並在真空及40℃下乾燥(10mbar)。
熔點：270-274℃(熔融/分解)
該標題產物係藉由其粉末繞射圖分析特徵，其進行方式係取50mg實例1化合物置於兩個Kapton®薄膜之間或置於載體上，並加載於呈具有3-55°的2θ角範圍(0.017°步進及35.5s/步進)的傳輸模式之Panalytical Xpert-Pro MPD繞射儀(銅陽極)中，此使得可判定以下結晶參數：晶胞參數：a=15.0958(5)Å，b=18.4586(6)Å，c=8.8269(2)Å，β=94.074(1)°，γ=90°
空間群：C 1 c 1(9)
晶胞體積：V晶胞=2453.37600Å3
該標題產物亦藉由實例1化合物之單晶X射線繞射分析特徵，其係藉助Rigaku XtaLAB裝置，使用石墨單色Mo-Ka輻射進行。觀察到以下結晶參數：晶胞參數：a=14.995(4)Å，b=18.302(4)Å，c=8.850(2)Å，β=93.528(7)°，γ=90°
空間群：C 1 c 1(9)
晶胞體積：V晶胞=2424.0(9)Å3
在使用粉末所得到的參數中所觀察到之微小差異歸因於用於得到單晶參數之溫度(-100℃)，其引起沿軸線a及b之收縮。
該標題產物亦藉由於其顯示於圖1中之X射線粉末繞射圖分析特徵，其係利用Panalytical Xpert-Pro MPD繞射儀(銅陽極)測定，並以平
面間距d、布拉格(Bragg's)角2θ(以°±0.2表示)及相對強度(以相對於最高強度直線的百分比表示)表示：
X射線粉末繞射圖之布拉格角2θ(以°±0.2表示)特徵：12.86、15.13、15.50、17.70、18.25、18.71、20.11、21.46、21.67、21.89、22.29、22.58、24.57、25.82、26.33。
實例1化合物之特徵亦在於其DSC圖，其中將5-10mg樣品加載於TA InstrumentsDSC Q1000裝置中並冷卻至0℃。然後以10℃/min之速率加熱該樣品至300℃。得到的圖係示於圖2中。
實例2：3-[(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮甲磺酸鹽(Z型異構體)在變性條件下之純度及安定性
實例3：3-[(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮甲磺酸鹽(Z型異構體)之溶解度
在室溫下攪拌含有溶於7ml水中之於實例1中得到的140mg化合物的溶液24小時。使用Acrodisc GHP 0.45μm過濾後，藉由HPLC分析該溶液。實例1化合物之溶解度係14.7mg/ml(或就鹼當量而言係12.1mg/ml)。
在相同條件下，3-[(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮之鹽酸鹽(Z型異構體)之溶解度係4.3mg/ml(或就鹼當量而言係4mg/ml)。
實例4：3-[(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮甲磺酸鹽(Z型異構體)在pH2下(胃pH)之溶解動力學
在室溫及pH2(10mL的0.01N HCl)下，使用μDiss溶解裝置及0.075cm2丸劑(在90bar下壓縮製成)，在100rpm攪拌速率下測定實例1產物之恆定表面積溶解動力學(或固有溶解動力學)2分鐘。
實例1產物以23μg.s-1.cm-2 +/- 11%之動力學溶解。相比較而言，相應鹽酸鹽之溶解動力學係1.6μg.s-1.cm-2。
因此，該甲磺酸鹽的溶解速率比相應鹽酸鹽的溶解速率快約14倍。
實例5：醫藥組合物
1000個錠劑，每個錠劑含有5mg劑量之3-[(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮。
圖1顯示本發明化合物之X射線粉末繞射圖。
圖2顯示實例1化合物之DSC圖。
Claims (14)
- 一種式(II)之3-[(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮甲磺酸鹽，
- 如請求項1之化合物，其係3-[(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮甲磺酸鹽之Z型異構體。
- 如請求項1或2之化合物，其中該化合物之X射線粉末繞射圖具有以下布拉格(Bragg's)角2θ(以°±0.2表示)：12.86、15.13、15.50、17.70、18.25、18.71、20.11、21.46、21.67、21.89、22.29、22.58、24.57、25.82、26.33。
- 如請求項1或2之化合物，其中該化合物具有自粉末繞射圖獲得之以下參數，該粉末繞射係在呈具有3-55°的2θ角範圍(0.017°步進及35.5s/步進)的傳輸模式之Panalytical Xpert-Pro MPD繞射儀(銅陽極)上進行，此使得可判定以下結晶參數：晶胞參數：a=15.0958(5)Å，b=18.4586(6)Å，c=8.8269(2)Å，β=94.074(1)°，γ=90°空間群：C 1 c 1(9)晶胞體積：V晶胞=2453.37600Å3。
- 一種獲得如請求項1之式(II)化合物之方法，其特徵在於：使用3- [(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮作為起始材料，將其溶解於溶劑/水的二元系統中，向其中添加1至2莫耳當量的甲磺酸，攪拌直至甲磺酸鹽沉澱析出並濾出該甲磺酸鹽。
- 一種獲得如請求項1之式(II)化合物之方法，其特徵在於：使用3-[(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮鹽酸鹽作為起始材料，將其溶解於溶劑/水的二元系統中，藉由添加鹼將其pH調節至8，藉由過濾除去所形成的鹽，然後加熱濾液並添加甲磺酸，且攪拌及冷卻該介質，直至甲磺酸鹽沉澱析出並濾出該甲磺酸鹽。
- 一種醫藥組合物，其包含如請求項1至4中任一項之式(II)化合物及一種或多種醫藥上可接受之賦形劑。
- 如請求項7之醫藥組合物，其中該式(II)化合物係3-[(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮甲磺酸鹽之Z型異構體。
- 如請求項7或8之醫藥組合物，其係用於製造用以治療結腸癌、乳癌、肝癌、腎癌、腦癌及食道癌、黑素瘤、骨髓瘤、卵巢癌、非小細胞性肺癌、小細胞性肺癌、前列腺癌及胰臟癌或肉瘤之藥劑。
- 一種如請求項1至4中任一項之式(II)化合物與抗癌劑之締合物，該抗癌劑係選自遺傳毒性劑、有絲分裂毒劑、抗代謝物、蛋白酶體抑制劑及激酶抑制劑。
- 如請求項10之締合物，其中該式(II)化合物係3-[(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮甲磺酸鹽之Z型異構體。
- 一種如請求項10或11之締合物之用途，其係製造用於治療癌症之藥劑。
- 一種如請求項1至4中任一項之式(II)化合物之用途，其係與放射療法結合製造用於治療癌症之藥劑。
- 如請求項13之用途，其中該式(II)化合物係3-[(3-{[4-(4-嗎啉基甲基)-1H-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1H-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮甲磺酸鹽之Z型異構體。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1356870A FR3008411B1 (fr) | 2013-07-12 | 2013-07-12 | Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201504236A TW201504236A (zh) | 2015-02-01 |
| TWI554510B true TWI554510B (zh) | 2016-10-21 |
Family
ID=50424327
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW103124019A TWI554510B (zh) | 2013-07-12 | 2014-07-11 | ３－［（３－｛［４－（４－嗎啉基甲基）－１ｈ－吡咯－２－基］亞甲基｝－２－側氧基－２，３－二氫－１ｈ－吲哚－５－基）甲基］－１，３－噻唑啶－２，４－二酮之新穎鹽，其製備方法，及包含其之調配物 |
| TW105105577A TW201630906A (zh) | 2013-07-12 | 2014-07-11 | ３-［（３-｛［４-（４-嗎啉基甲基）-１ｈ-吡咯-２-基］亞甲基｝-２-側氧基-２，３-二氫-１ｈ-吲哚-５-基）甲基］-１，３-噻唑啶-２，４-二酮之新穎鹽，其製備方法，及包含其之調配物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105105577A TW201630906A (zh) | 2013-07-12 | 2014-07-11 | ３-［（３-｛［４-（４-嗎啉基甲基）-１ｈ-吡咯-２-基］亞甲基｝-２-側氧基-２，３-二氫-１ｈ-吲哚-５-基）甲基］-１，３-噻唑啶-２，４-二酮之新穎鹽，其製備方法，及包含其之調配物 |
Country Status (47)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10245270B2 (en) * | 2013-07-12 | 2019-04-02 | Les Laboratoires Servier | Salt of 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, its preparation, and formulations containing it |
| FR3039401B1 (fr) * | 2015-07-31 | 2018-07-13 | Les Laboratoires Servier | Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200804239A (en) * | 2005-12-05 | 2008-01-16 | Xenoport Inc | Levodopa prodrug mesylate, compositions thereof, and uses thereof |
| TW201118092A (en) * | 2009-08-04 | 2011-06-01 | Servier Lab | New dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK287142B6 (sk) * | 2000-02-15 | 2010-01-07 | Sugen, Inc. | Inhibítory proteínkináz na báze pyrolom substituovaného 2-indolinónu, farmaceutický prípravok s ich obsahom a ich použitie |
| ATE303998T1 (de) * | 2000-10-17 | 2005-09-15 | Merck & Co Inc | Oral aktive salze mit tyrosinkinaseaktivität |
| AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| IL162203A0 (en) * | 2001-12-27 | 2005-11-20 | Theravance Inc | Indolinone derivatives useful as protein inase inhibitors |
| RU2006117635A (ru) * | 2003-10-24 | 2007-12-10 | Шеринг Акциенгезельшафт (De) | Производные индолинона и их применение для лечения патологических состояний, таких как злокачественное новообразование |
-
2013
- 2013-07-12 FR FR1356870A patent/FR3008411B1/fr active Active
-
2014
- 2014-06-26 UY UY0001035629A patent/UY35629A/es unknown
- 2014-06-29 JO JOP/2014/0205A patent/JO3292B1/ar active
- 2014-07-11 UA UAA201600944A patent/UA114041C2/uk unknown
- 2014-07-11 MY MYPI2016700018A patent/MY183197A/en unknown
- 2014-07-11 TN TN2015000566A patent/TN2015000566A1/fr unknown
- 2014-07-11 LT LTEP14758600.2T patent/LT3019497T/lt unknown
- 2014-07-11 HU HUE14758600A patent/HUE032568T2/hu unknown
- 2014-07-11 RS RS20170461A patent/RS55945B1/sr unknown
- 2014-07-11 GE GEAP201414051A patent/GEP201706712B/en unknown
- 2014-07-11 JP JP2016524879A patent/JP6532459B2/ja not_active Expired - Fee Related
- 2014-07-11 CN CN201480038854.7A patent/CN105377843B/zh not_active Expired - Fee Related
- 2014-07-11 DK DK14758600.2T patent/DK3019497T3/en active
- 2014-07-11 MD MDA20160003A patent/MD4507C1/ro not_active IP Right Cessation
- 2014-07-11 SI SI201430246A patent/SI3019497T1/sl unknown
- 2014-07-11 MX MX2016000332A patent/MX360291B/es active IP Right Grant
- 2014-07-11 ME MEP-2017-149A patent/ME02735B/me unknown
- 2014-07-11 ES ES14758600.2T patent/ES2632570T3/es active Active
- 2014-07-11 PE PE2015002679A patent/PE20160079A1/es unknown
- 2014-07-11 EP EP14758600.2A patent/EP3019497B1/fr active Active
- 2014-07-11 KR KR1020187006643A patent/KR20180028554A/ko not_active Application Discontinuation
- 2014-07-11 NZ NZ715841A patent/NZ715841A/en not_active IP Right Cessation
- 2014-07-11 EA EA201600101A patent/EA031526B1/ru not_active IP Right Cessation
- 2014-07-11 CA CA2916380A patent/CA2916380C/fr not_active Expired - Fee Related
- 2014-07-11 SG SG11201510570YA patent/SG11201510570YA/en unknown
- 2014-07-11 AP AP2016008976A patent/AP2016008976A0/xx unknown
- 2014-07-11 AU AU2014289059A patent/AU2014289059B2/en not_active Ceased
- 2014-07-11 US US14/904,260 patent/US9925195B2/en not_active Expired - Fee Related
- 2014-07-11 TW TW103124019A patent/TWI554510B/zh not_active IP Right Cessation
- 2014-07-11 MA MA38759A patent/MA38759B1/fr unknown
- 2014-07-11 TW TW105105577A patent/TW201630906A/zh unknown
- 2014-07-11 PT PT147586002T patent/PT3019497T/pt unknown
- 2014-07-11 AR ARP140102566A patent/AR096882A1/es unknown
- 2014-07-11 KR KR1020167003298A patent/KR20160030399A/ko active Application Filing
- 2014-07-11 PL PL14758600T patent/PL3019497T3/pl unknown
- 2014-07-11 RU RU2016104642A patent/RU2680826C9/ru not_active IP Right Cessation
- 2014-07-11 WO PCT/FR2014/051783 patent/WO2015004395A1/fr active Application Filing
-
2016
- 2016-01-04 PH PH12016500017A patent/PH12016500017A1/en unknown
- 2016-01-06 CL CL2016000013A patent/CL2016000013A1/es unknown
- 2016-01-07 DO DO2016000005A patent/DOP2016000005A/es unknown
- 2016-01-07 CR CR20160012A patent/CR20160012A/es unknown
- 2016-01-10 IL IL243526A patent/IL243526B/en not_active IP Right Cessation
- 2016-01-11 NI NI201600009A patent/NI201600009A/es unknown
- 2016-01-11 GT GT201600004A patent/GT201600004A/es unknown
- 2016-01-12 SA SA516370388A patent/SA516370388B1/ar unknown
- 2016-01-12 CU CUP2016000005A patent/CU20160005A7/es unknown
- 2016-08-30 HK HK16110306.0A patent/HK1222172A1/zh unknown
- 2016-09-13 HK HK16110825.2A patent/HK1222655A1/zh not_active IP Right Cessation
-
2017
- 2017-07-04 CY CY20171100714T patent/CY1119259T1/el unknown
- 2017-07-11 HR HRP20171060TT patent/HRP20171060T1/hr unknown
-
2018
- 2018-02-14 US US15/896,273 patent/US20180207171A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200804239A (en) * | 2005-12-05 | 2008-01-16 | Xenoport Inc | Levodopa prodrug mesylate, compositions thereof, and uses thereof |
| TW201118092A (en) * | 2009-08-04 | 2011-06-01 | Servier Lab | New dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7383652B2 (ja) | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 | |
| TWI557123B (zh) | 結晶型（８Ｓ，９Ｒ）－５－氟－８－（４－氟苯基）－９－（１－甲基－１Ｈ－１，２，４－三唑－５－基）－８，９－二氫－２Ｈ－吡啶并［４，３，２－ｄｅ］呔－３（７Ｈ）－酮甲苯磺酸鹽 | |
| JP5916752B2 (ja) | ５−クロロ−ｎ２−（２−イソプロポキシ−５−メチル−４−ピペリジン−４−イル−フェニル）−ｎ４［２−（プロパン−２−スルホニル）−フェニル］−ピリミジン−２，４−ジアミンの結晶形 | |
| JP7432590B2 (ja) | 選択的ｃｄｋ９阻害剤としての酒石酸塩及びその結晶形 | |
| JP2001504109A (ja) | ベンゾ複素環ジスタマイシン誘導体、それらを製造する方法および抗腫瘍および抗ウイルス剤としてのそれらの用途 | |
| JP2019518776A (ja) | Ｅｇｆｒ阻害剤としてのアニリンピリミジン化合物の結晶 | |
| TWI554510B (zh) | ３－［（３－｛［４－（４－嗎啉基甲基）－１ｈ－吡咯－２－基］亞甲基｝－２－側氧基－２，３－二氫－１ｈ－吲哚－５－基）甲基］－１，３－噻唑啶－２，４－二酮之新穎鹽，其製備方法，及包含其之調配物 | |
| JP2018516912A (ja) | アプレミラストおよびその新規な多形の改善された製造方法 | |
| KR20210024004A (ko) | Cdk4/6의 활성을 억제하기 위한 화합물의 결정 형태 및 그것의 용도 | |
| KR20220016949A (ko) | Cdk9 억제제의 결정다형 및 이의 제조방법과 용도 | |
| CN113316471A (zh) | 7-环戊基-2-(5-哌嗪-1-基-吡啶-2-基氨基)-7H-吡咯并[2,3-d]嘧啶-6-羧酸二甲基酰胺的琥珀酸盐的新的结晶形式 | |
| WO2016110243A1 (zh) | 一种酪氨酸激酶抑制剂的苹果酸盐的结晶形式及其制备方法 | |
| WO2016187028A1 (en) | Heteroaryl compounds, synthesis thereof, and intermediates thereto | |
| CN111566101B (zh) | Cdk4/6抑制剂及其药学上可接受的盐和多晶型物及其应用 | |
| US10245270B2 (en) | Salt of 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, its preparation, and formulations containing it | |
| KR20200092945A (ko) | 레날리도마이드의 결정형 | |
| TW201008936A (en) | Crystalline forms of thiazolidinedione compound and its manufacturing method | |
| TWI344462B (en) | Indole derivatives having an apoptosis-inducing effect | |
| KR20230062917A (ko) | 피마살탄 일수화물 b형 결정다형 및 그 제조방법 | |
| OA17666A (fr) | Nouveau sel de la 3-[(3-{[4-(4Morpholinylméthyl)-1H-Pyrrol-2-YL]Methylène}-2Oxo-2,3-Dihydro-1H-Indol-5-YL)Méthyl]-1,3-Thiazolidine-2,4-Dione, sa préparation, et les formulations qui le contiennent. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |